Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.18 USD

41.18
3,306,805

+0.86 (2.13%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer

AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.

How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry

GlaxoSmithKline (GSK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Here's Why You Should Hold on to Thermo Fisher Stock for Now

Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar segmental performance.

Pfizer (PFE) Sees a Difficult 2019: Can it Rebound in 2020?

Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.

Gilead (GILD) Partners With Eisai for RA Candidate in Japan

Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.

Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?

Is (GSK) Outperforming Other Medical Stocks This Year?

AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod

AstraZeneca (AZN) gets approval in China for PT010, its triple-combo inhaler, a fixed-dose ICS/LABA/LAMA inhaler, to treat COPD.

The Zacks Analyst Blog Highlights: JPMorgan, Boeing, NVIDIA, AstraZeneca and GlaxoSmithKline

The Zacks Analyst Blog Highlights: JPMorgan, Boeing, NVIDIA, AstraZeneca and GlaxoSmithKline

GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA

GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.

AstraZeneca Gets FDA Nod for New Breast Cancer Drug Enhertu

AstraZeneca's (AZN) antibody drug conjugate candidate, Enhertu gets FDA approval for treating HER2-positive breast cancer in third or later-line setting.

How Trading Your Own Retirement Can Fleece Your Financial Future - December 23, 2019

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication

The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).

Kinjel Shah headshot

Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs

Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.

Merck's Ebola Vaccine Ervebo Gets Approval in United States

FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.

Powerful Proof Anyone Can Invest for an Early Retirement - December 20, 2019

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Mark Vickery headshot

Top Analyst Reports for JPMorgan, Boeing & NVIDIA

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Boeing (BA) and NVIDIA (NVDA).

Pfizer's Braftovi sNDA Accepted by FDA for Priority Review

FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.

Novartis' Asthma Candidate Fails in LUSTER Phase III Studies

Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.

Myriad Genetics Presents Trial Outcomes in Breast Health

Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

GlaxoSmithKline (GSK) closed the most recent trading day at $45.93, moving -0.78% from the previous trading session.

Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy

Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.

Iterum Down as Sulopenem Antibiotic Fails in Phase III Study

Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.

Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA

The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.

Gilead (GILD) Announces Positive Long-Term Data on Yescarta

Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ

The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.